The U.S. Food and Drug Administration (FDA) has approved vimseltinib (RomvimzaTM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue that lines the joints.
Vimseltinib gains FDA approval for treating tenosynovial giant cell tumor
- Post author:admin
- Post published:February 20, 2025
- Post category:uncategorized